atopic dermatitis

Dupilumab (REGN-668) is a fully human monoclonal antibody targeting the alpha subunit of the interleukin-4 receptor, thereby inhibiting IL-4 and IL-13 signaling. As a systemic immunomodulator, it has demonstrated efficacy in improving atopic dermatitis.

Etokimab (Antibody ANB 020), a humanized monoclonal antibody, specifically targets IL-33. It is utilized in the research of atopic dermatitis [1].

Tralokinumab is a fully human IgG4 monoclonal antibody with a high affinity for IL-13 alone. Tralokinumab's potential anti-inflammatory activity prevents IL-13 receptor interaction and subsequent downstream signaling and can be used to study atopic dermatitis (AD).

Nemolizumab (CIM331) is a humanized monoclonal antibody targeting the human interleukin-31 receptor A, inhibiting IL-31 binding and subsequent signal transduction. It is useful for studying atopic dermatitis with pruritus.

Fezakinumab is a potent monoclonal antibody to interleukin-22 (IL-22). Fezakinumab can be used to study immune system diseases and inflammation-related conditions such as psoriasis, rheumatoid arthritis and atopic dermatitis.

Lokivetmab, an Anti-Canine IL31 Recombinant Antibody, is a monoclonal antibody targeting canine IL-31, utilized in research related to atopic dermatitis (AD) in dogs [1].

Spesolimab (BI 655130) is an anti-interleukin-36 receptor antibody. It plays a crucial role in the immune system by reducing biomarkers associated with congenital Th1 Th17 and neutrophil pathways. Spesolimab can be used to study systemic pustular psoriasis, palmar and plantar impetigo (PPP), and atopic dermatitis.

Cendakimab (RPC4046) is a humanized monoclonal antibody targeting IL-13. It selectively targets the IL-13 receptor (IL13R-α1 and IL13R-α2), used in research on atopic dermatitis.

Telazorlimab (GBR-830) is a humanized monoclonal antibody targeting the OX40 co-stimulatory receptor on activated T cells, and is used to treat lupus erythematosus and atopic dermatitis.

Apamistamab (Anti-CD45 antibody) is a humanized antibody targeting CD45, which can be used to study atopic dermatitis.

Amlitelimab (KY1005) is a monoclonal antibody targeting OX40 ligand (OX40L), inhibiting KLH-driven immune responses, used in the study of atopic dermatitis.

Rocatinlimab (AMG 451) (KHK4083) is a fully human, non-fucosylated IgG1 anti-OX40 monoclonal antibody indicated for atopic dermatitis (AD) research [1].

Eblasakimab (ASLAN004) is a humanized monoclonal antibody targeting the IL-13 receptor alpha. By blocking IL-4 and IL-13 signaling through type 2 receptor inhibition, it can be used for studying atopic dermatitis.

Stapokibart (CM310) is a humanized monoclonal antibody targeting IL-4Rα, blocking IL-4Rα-mediated signaling. It is used in studies of atopic dermatitis.